Literature DB >> 29400704

Functions of NKG2D in CD8+ T cells: an opportunity for immunotherapy.

Kushal Prajapati1, Cynthia Perez1, Lourdes Beatriz Plaza Rojas1, Brianna Burke1, Jose A Guevara-Patino2.   

Abstract

Natural killer group 2 member D (NKG2D) is a type II transmembrane receptor. NKG2D is present on NK cells in both mice and humans, whereas it is constitutively expressed on CD8+ T cells in humans but only expressed upon T-cell activation in mice. NKG2D is a promiscuous receptor that recognizes stress-induced surface ligands. In NK cells, NKG2D signaling is sufficient to unleash the killing response; in CD8+ T cells, this requires concurrent activation of the T-cell receptor (TCR). In this case, the function of NKG2D is to authenticate the recognition of a stressed target and enhance TCR signaling. CD28 has been established as an archetype provider of costimulation during T-cell priming. It has become apparent, however, that signals from other costimulatory receptors, such as NKG2D, are required for optimal T-cell function outside the priming phase. This review will focus on the similarities and differences between NKG2D and CD28; less well-described characteristics of NKG2D, such as the potential role of NKG2D in CD8+ T-cell memory formation, cancer immunity and autoimmunity; and the opportunities for targeting NKG2D in immunotherapy.

Entities:  

Keywords:  Auto-immunity; CD28; CD8+ T Cell; Cancer; Immunity; Immunotherapy; Memory; NKG2D

Mesh:

Substances:

Year:  2018        PMID: 29400704      PMCID: PMC6068164          DOI: 10.1038/cmi.2017.161

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   11.530


  84 in total

1.  NKG2D receptor regulates human effector T-cell cytokine production.

Authors:  Amorette Barber; Charles L Sentman
Journal:  Blood       Date:  2011-04-25       Impact factor: 22.113

Review 2.  An enigmatic tail of CD28 signaling.

Authors:  Jonathan S Boomer; Jonathan M Green
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-06-09       Impact factor: 10.005

3.  Engagement of NKG2D by cognate ligand or antibody alone is insufficient to mediate costimulation of human and mouse CD8+ T cells.

Authors:  Lauren I Richie Ehrlich; Kouetsu Ogasawara; Jessica A Hamerman; Rayna Takaki; Alessandra Zingoni; James P Allison; Lewis L Lanier
Journal:  J Immunol       Date:  2005-02-15       Impact factor: 5.422

4.  Promoter region architecture and transcriptional regulation of the genes for the MHC class I-related chain A and B ligands of NKG2D.

Authors:  Gopalakrishnan M Venkataraman; Dominic Suciu; Veronika Groh; Jeremy M Boss; Thomas Spies
Journal:  J Immunol       Date:  2007-01-15       Impact factor: 5.422

5.  NKG2D signaling on CD8⁺ T cells represses T-bet and rescues CD4-unhelped CD8⁺ T cell memory recall but not effector responses.

Authors:  Andrew Zloza; Frederick J Kohlhapp; Gretchen E Lyons; Jason M Schenkel; Tamson V Moore; Andrew T Lacek; Jeremy A O'Sullivan; Vineeth Varanasi; Jesse W Williams; Michael C Jagoda; Emily C Bellavance; Amanda L Marzo; Paul G Thomas; Biljana Zafirova; Bojan Polić; Lena Al-Harthi; Anne I Sperling; José A Guevara-Patiño
Journal:  Nat Med       Date:  2012-02-26       Impact factor: 53.440

6.  Molecular cloning and characterization of pig immunoreceptor DAP10 and NKG2D.

Authors:  D Yim; H B Jie; J Sotiriadis; Y S Kim; K S Kim; M F Rothschild; L L Lanier; Y B Kim
Journal:  Immunogenetics       Date:  2001-04       Impact factor: 2.846

7.  Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.

Authors:  Nicole Schwinn; Daria Vokhminova; Antje Sucker; Sonja Textor; Sandra Striegel; Iris Moll; Norman Nausch; Jochen Tuettenberg; Alexander Steinle; Adelheid Cerwenka; Dirk Schadendorf; Annette Paschen
Journal:  Int J Cancer       Date:  2009-04-01       Impact factor: 7.396

8.  The expression and function of NKG2D molecule on intrahepatic CD8+ T cells in chronic viral hepatitis.

Authors:  P T F Kennedy; A J Gehring; A Nowbath; C Selden; A Quaglia; A Dhillon; G Dusheiko; A Bertoletti
Journal:  J Viral Hepat       Date:  2008-12       Impact factor: 3.728

9.  NKG2D blockade prevents autoimmune diabetes in NOD mice.

Authors:  Kouetsu Ogasawara; Jessica A Hamerman; Lauren R Ehrlich; Helene Bour-Jordan; Pere Santamaria; Jeffrey A Bluestone; Lewis L Lanier
Journal:  Immunity       Date:  2004-06       Impact factor: 31.745

10.  Functional dichotomy between NKG2D and CD28-mediated co-stimulation in human CD8+ T cells.

Authors:  Kamalakannan Rajasekaran; Va Xiong; Lee Fong; Jack Gorski; Subramaniam Malarkannan
Journal:  PLoS One       Date:  2010-09-09       Impact factor: 3.240

View more
  33 in total

1.  CD28H expression identifies resident memory CD8 + T cells with less cytotoxicity in human peripheral tissues and cancers.

Authors:  Yu Tian; Yi Sun; Fan Gao; Michelle R Koenig; Alexander Sunderland; Yuki Fujiwara; Robert J Torphy; Lieping Chen; Barish H Edil; Richard D Schulick; Yuwen Zhu
Journal:  Oncoimmunology       Date:  2018-11-05       Impact factor: 8.110

2.  Virtual memory CD8+ T cells restrain the viral reservoir in HIV-1-infected patients with antiretroviral therapy through derepressing KIR-mediated inhibition.

Authors:  Jie-Hua Jin; Hui-Huang Huang; Ming-Ju Zhou; Jing Li; Wei Hu; Lei Huang; Zhe Xu; Bo Tu; Guang Yang; Ming Shi; Yan-Mei Jiao; Xing Fan; Jin-Wen Song; Ji-Yuan Zhang; Chao Zhang; Fu-Sheng Wang
Journal:  Cell Mol Immunol       Date:  2020-03-24       Impact factor: 11.530

Review 3.  Role of NKG2D and its ligands in cancer immunotherapy.

Authors:  Huifang Liu; Sijia Wang; Jing Xin; Jing Wang; Cuiping Yao; Zhenxi Zhang
Journal:  Am J Cancer Res       Date:  2019-10-01       Impact factor: 6.166

4.  Adoptive T-Cell Transfer to Treat Lymphangioleiomyomatosis.

Authors:  Fei Han; Emilia R Dellacecca; Levi W Barse; Cormac Cosgrove; Steven W Henning; Christian M Ankney; Dinesh Jaishankar; Alexander Yemelyanov; Vera P Krymskaya; Daniel F Dilling; I Caroline Le Poole
Journal:  Am J Respir Cell Mol Biol       Date:  2020-06       Impact factor: 6.914

5.  A novel lipidic peptide with potential to promote balanced effector-regulatory T cell responses.

Authors:  Michael Agrez; Justyna Rzepecka; Darryl Turner; Gavin Knox; Christopher Chandler; Christopher B Howard; Nicholas Fletcher; Kristofer Thurecht; Stephen Parker; Hayley Gooding; Laura Gallagher
Journal:  Sci Rep       Date:  2022-07-01       Impact factor: 4.996

Review 6.  Bystander T cells in cancer immunology and therapy.

Authors:  Stefanie L Meier; Ansuman T Satpathy; Daniel K Wells
Journal:  Nat Cancer       Date:  2022-02-28

7.  The natural killer cell activating receptor, NKG2D, is critical to antibody-dependent chronic rejection in heart transplantation.

Authors:  Christine M Lin; Ronald G Gill; Borna Mehrad
Journal:  Am J Transplant       Date:  2021-06-17       Impact factor: 9.369

8.  NKG2D Enhances Double-Negative T Cell Regulation of B Cells.

Authors:  Shi-Hua Hu; Long-Hui Zhang; Jie Gao; Jing-Heng Guo; Xiao-Dong Xun; Xiao Xiang; Qian Cheng; Zhao Li; Ji-Ye Zhu
Journal:  Front Immunol       Date:  2021-06-16       Impact factor: 7.561

9.  Co-delivery of novel bispecific and trispecific engagers by an amplicon vector augments the therapeutic effect of an HSV-based oncolytic virotherapy.

Authors:  Divya Ravirala; Brandon Mistretta; Preethi H Gunaratne; Guangsheng Pei; Zhongming Zhao; Xiaoliu Zhang
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751

Review 10.  Chimeric non-antigen receptors in T cell-based cancer therapy.

Authors:  Jitao Guo; Andrew Kent; Eduardo Davila
Journal:  J Immunother Cancer       Date:  2021-08       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.